Biology Reference
In-Depth Information
Beuckelmann DJ, Nabauer M, Erdmann E (1992) Intracellular calcium handling in isolated
ventricular myocytes from patients with terminal heart failure. Circulation 85:1046-1055
Bristow MR, Ginsburg R, Umans V et al (1986) Beta 1- and beta 2-adrenergic-receptor subpopu-
lations in nonfailing and failing human ventricular myocardium: coupling of both receptor
subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.
Circ Res 59:297-309
Choi YH, Ekholm D, Krall J et al (2001) Identification of a novel isoform of the cyclic-nucleotide
phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes. Biochem J 353:41-50
Das A, Xi L, Kukreja RC (2005) Phosphodiesterase-5 inhibitor sildenafil preconditions adult
cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol
Chem 280:12944-12955
Das A, Xi L, Kukreja RC (2008) Protein kinase G-dependent cardioprotective mechanism of
phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem
283:29572-29585
Das A, Salloum FN, Xi L, Rao YJ, Kukreja RC (2009) ERK phosphorylation mediates sildenafil-
induced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol
Heart Circ Physiol 296:H1236-H1243
Dieterle T, Meyer M, Gu Y et al (2005) Gene transfer of a phospholamban-targeted antibody
improves calcium handling and cardiac function in heart failure. Cardiovasc Res 67:678-688
Ding B, Abe J, Wei H et al (2005a) Functional role of phosphodiesterase 3 in cardiomyocyte
apoptosis: implication in heart failure. Circulation 111:2469-2476
Ding B, Abe J, Wei H et al (2005b) A positive feedback loop of phosphodiesterase 3 (PDE3) and
inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci
USA 102:14771-14776
Dorn GW 2nd (2009) Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricu-
lar remodelling. Cardiovasc Res 81:465-473
Drakos SG, Kanakakis JV, Nanas S et al (2009) Intermittent inotropic infusions combined with
prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
J Cardiovasc Pharmacol 53:157-161
Eizema K, Fechner H, Bezstarosti K et al (2000) Adenovirus-based phospholamban antisense
expression as a novel approach to improve cardiac contractile dysfunction: comparison of a
constitutive viral versus an endothelin-1-responsive cardiac promoter. Circulation 101:2193-2199
Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC (2005) Phosphodiesterase-5 inhibition with
sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic
model of doxorubicin cardiotoxicity. Circulation 111:1601-1610
Frace AM, Mery PF, Fischmeister R, Hartzell HC (1993) Rate-limiting steps in the beta-adrenergic
stimulation of cardiac calcium current. J Gen Physiol 101:337-353
Francis SH, Corbin JD (2005) Sildenafil: efficacy, safety, tolerability and mechanism of action in
treating erectile dysfunction. Expert Opin Drug Metab Toxicol 1:283-293
Garlid KD, Costa AD, Quinlan CL, Pierre SV, Dos Santos P (2009) Cardioprotective signaling to
mitochondria. J Mol Cell Cardiol 46:858-866
Hambleton R, Krall J, Tikishvili E et al (2005) Isoforms of cyclic nucleotide phosphodiesterase
PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human
myocardium. J Biol Chem 280:39168-39174
Han SJ, Vaccari S, Nedachi T et al (2006) Protein kinase B/Akt phosphorylation of PDE3A and its
role in mammalian oocyte maturation. EMBO J 25:5716-5725
Hassan MA, Ketat AF (2005) Sildenafil citrate increases myocardial cGMP content in rat heart,
decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine
kinase and troponin T. BMC Pharmacol 5:10
He H, Meyer M, Martin JL et al (1999) Effects of mutant and antisense RNA of phospho-
lamban on SR Ca(2+)-ATPase activity and cardiac myocyte contractility. Circulation
100:974-980
